FEMS Microbiology Letters · 2010 · 85 citations · 21 references
PharmacyInfectious DiseasesPharmacotherapyAntimicrobial PharmacologyAntimicrobial PharmacotherapyMycologyAntifungal AgentsAntifungal PharmacotherapyAntifungal ResistanceAntifungal TherapyFungal InfectionsFungal PathogenesisAdditive Drug InteractionsAntifungal Combination TherapyAntifungal Susceptibility TestingBroth MicrodilutionCombination Antifungal TherapyOpportunistic Fungal InfectionsSynergistic Drug CombinationsSynergistic Drug Interactions
The treatment of opportunistic fungal infections is often difficult as the number of available antifungal agents is limited. Nowadays, there is increasing interest in the investigation of the antifungal activity of nonantifungal drugs, and in the development of efficient antifungal combination therapy. In this study, the in vitro interactions of the effects of various statins (lovastatin, simvastatin, fluvastatin, atorvastatin (ATO), rosuvastatin (ROS) and pravastatin) and various azole antifungals [miconazole, ketoconazole, itraconazole and fluconazole (FLU)] against different opportunistic pathogenic fungi were investigated using a standard chequerboard broth microdilution method. When the investigated strains were sensitive to both compounds of the combination, additive interactions were frequently noticed. Synergistic interactions were observed in many cases when a strain was sensitive only to the azole compound (as in certain combinations with ATO or ROS) or the statin compound (as in certain combinations with FLU). In many combinations with an additive effect, the concentrations of drugs needed for total growth inhibition could be decreased by several dilution steps. Similar interactions were observed when the variability of the within-species sensitivities to some selected drug combinations was investigated.
21
Volker Fischer, Laurie Johanson, Francis Heitz et al. · Drug Metabolism and Disposition · 1999 · 148 citations
Medicine, Biochemistry, Pharmacology +17